Nanobiotix: Stifel initiates coverage as a buyer

(CercleFinance.com) - Stifel initiates coverage of Nanobiotix shares with a 'buy' recommendation and a target price of E16, implying a huge 304% upside potential for the biotech company's shares.


NBTXR3, Nanobiotix's most advanced asset, is an innovative radioenhancer designed to improve the efficacy of radiotherapy by amplifying the radiation dose intra-tumor, triggering both local and systemic responses, it explains.

The broker also points out that the company is already planning to explore all facets of nanoparticles across all therapeutic areas, as illustrated by the launch of the Curadigm platform in 2019 and the recent unveiling of Oocuity.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.